Unicycive Therapeutics
UNCY
16 hedge funds and large institutions have $12.2M invested in Unicycive Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 5 closing their positions.
787% more capital invested
Capital invested by funds: $1.38M → $12.2M (+$10.8M)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
7% more funds holding
Funds holding: 15 → 16 (+1)
3.38% more ownership
Funds ownership: 0.71% → 4.08% (+3.4%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$3.25M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$3.25M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$3.2M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.64M |
| 5 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
+$11.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
-$25.6K |
| 2 |
Two Sigma Advisers
New York
|
-$19.5K |
| 3 |
CC
Centiva Capital
New York
|
-$19.4K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$18.5K |
| 5 |
OA
Oxbow Advisors
Austin,
Texas
|
-$15.2K |
UNCY Hedge Fund Activity: Q3 2023 in Review
16 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q3 2023, worth a combined $12.2M — up 787% from $1.38M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new UNCY positions and 5 closed out — a net gain of 1 holder — while 2 added to existing stakes and 4 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $3.25M. The largest seller was Ground Swell Capital, exiting entirely with an estimated $25.6K sold.
- 16 institutional investors held Unicycive Therapeutics (UNCY) as of Q3 2023, up from 15 in Q2 2023.
- Funds reported $12.2M of Unicycive Therapeutics stock for Q3 2023, up 787% quarter-over-quarter.
- 6 funds opened new Unicycive Therapeutics positions in Q3 2023 and 5 closed out, a net change of +1 holder.
- The largest Unicycive Therapeutics buyer in Q3 2023 was RA Capital Management, an estimated $3.25M added.
- The largest Unicycive Therapeutics seller in Q3 2023 was Ground Swell Capital, an estimated $25.6K sold.
Based on aggregated 13F filings for Q3 2023.